+114.0%
NFLX vs MRNA
+786.4%
-672.4%
-75.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.0% | -2.2% | -0.8% | -2.8% |
| 7D | -8.7% | -12.7% | +4.0% | -8.1% |
| 30D | -12.8% | -20.7% | +7.9% | -11.9% |
| 3M | -29.2% | +46.3% | -75.5% | -31.0% |
| 6M | -35.6% | +305.2% | -340.8% | -43.8% |
| YTD | -39.5% | +561.2% | -600.7% | -49.8% |
| 1Y | -46.3% | +772.1% | -818.4% | -56.6% |
| 3Y | +19.6% | +147.0% | -127.4% | +4.0% |
| 5Y | -16.4% | -26.1% | +9.6% | -22.1% |
| All | +114.0% | +786.4% | -672.4% | +67.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling